Dermatitis
Online Submission and Review System
Instructions for Authors (this page)
Copyright Transfer and Disclosure Form (PDF)
Reprint Ordering
Permissions Requests

INSTRUCTIONS FOR AUTHORS

SCOPE
Dermatitis provides clinically relevant articles on contact dermatitis, atopic dermatitis, occupational dermatitis, and drug reactions with skin manifestations. Comprehensive reviews, clinical and laboratory studies, case reports, and feature articles will be considered for publication. Most case reports are published online only. Authors are encouraged to submit case reports as Pearls and Zebra.

Manuscripts are accepted for consideration on the condition that they are contributed solely to Dermatitis. Manuscripts will be reviewed by the Editor-in-Chief, an Associate Editor, or a Section Editor, as well as by appropriate members of the Editorial Board or by other experts. Dermatitis is indexed and included in Index Medicus/MEDLINE, Excerpta Medica, and EMBASE.

Members of the American Contact Dermatitis Society receive Dermatitis as a benefit of membership. To learn more about the American Contact Dermatitis Society or to receive an application for membership, please direct your inquiry to:

American Contact Dermatitis Society,
555 East Wells Street, Suite 1100
Milwaukee, WI 53202
Phone: 414-918-9805
Fax: 414-276-3349
[email protected].

Ethical/Legal Considerations
A submitted manuscript must be an original contribution not previously published (except as an abstract or a preliminary report), must not be under consideration for publication elsewhere, and, if accepted, must not be published elsewhere in similar form, in any language, without the consent of Lippincott Williams & Wilkins. Each person listed as an author is expected to have participated in the study to a significant extent. Although the editors and referees make every effort to ensure the validity of published manuscripts, the final responsibility rests with the authors, not with the Journal, its editors, or the publisher. 

Patient anonymity and informed consent: It is the author's responsibility to ensure that a patient's anonymity be carefully protected and to verify that any experimental investigation with human subjects reported in the manuscript was performed with informed consent and following all the guidelines for experimental investigation with human subjects required by the institution(s) with which all the authors are affiliated. If identifying details do appear in text, tables, and/or figures, the author must provide proof of informed consent that he/she obtained from the patients (a signed permissions form). This informed consent should be indicated in the text of the article (in the Methods section, if appropriate) or in the acknowledgments at the end of the article. Photographs with bars placed over eyes of patients should NOT be used in publication unless permission from the patient is granted.

Copyright:
Conflicts of interest
Authors must state all possible conflicts of interest in the manuscript, including financial, consultant, institutional and other relationships that might lead to bias or a conflict of interest. If there is no conflict of interest, this should also be explicitly stated as none declared. All sources of funding should be acknowledged in the manuscript. All relevant conflicts of interest and sources of funding should be included on the title page of the manuscript with the heading “Conflicts of Interest and Source of Funding:”. For example:

Conflicts of Interest and Source of Funding: A has received honoraria from Company Z. B is currently receiving a grant (#12345) from Organization Y, and is on the speaker’s bureau for Organization X – the CME organizers for Company A. For the remaining authors none were declared.

In addition, each author must complete and submit the journal's copyright transfer agreement, which includes a section on the disclosure of potential conflicts of interest based on the recommendations of the International Committee of Medical Journal Editors, "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" (www.icmje.org/update.html).

A copy of the form is made available to the submitting author within the Editorial Manager submission process. Co-authors will automatically receive an Email with instructions on completing the form upon submission.

Open access
Authors of accepted peer-reviewed articles have the choice to pay a fee to allow perpetual unrestricted online access to their published article to readers globally, immediately upon publication. Authors may take advantage of the open access option at the point of submission. Please note that this choice has no influence on the peer review and acceptance process. These articles are subject to the journal's standard peer-review process and will be accepted or rejected based on their own merit.

The article processing charge (APC) is charged on acceptance of the article and should be paid within 30 days by the author, funding agency or institution. Payment must be processed for the article to be published open access. For a list of journals and pricing please visit our Wolters Kluwer Hybrid Open Access Journals page.

Authors retain copyright
Authors retain their copyright for all articles they opt to publish open access. Authors grant Wolters Kluwer an exclusive license to publish the article and the article is made available under the terms of a Creative Commons user license. Please visit our Open Access Publication Process page for more information.

Creative Commons license
Open access articles are freely available to read, download and share from the time of publication under the terms of the Creative Commons License Attribution-Non Commercial No Derivative (CC BY-NC-ND) license. This license does not permit reuse for any commercial purposes, nor does it cover the reuse or modification of individual elements of the work (such as figures, tables, etc.) in the creation of derivative works without specific permission.

Compliance with funder mandated open access policies
An author whose work is funded by an organization that mandates the use of the Creative Commons Attribution (CC BY) license is able to meet that requirement through the available open access license for approved funders. Information about the approved funders can be found here.

Read and Publish Agreements

Wolters Kluwer currently has read-and-publish agreements with institutional consortia listed here.

Corresponding authors who are affiliated with the participating institution and who qualify as eligible authors* can publish their eligible articles open access in the eligible LWW journals at no direct cost to them. Please see your institution’s individual policy for guidance on eligible article types and license choice. To qualify for the APC waiver, the corresponding author must provide their participating institution’s name and institutional email address in the journal’s submission system. On acceptance, the corresponding author will be asked to place an open access order in the publisher’s payment portal where they will be able to request the APC be funded in accordance with this agreement. A $0.00 APC will then be applied.

*Eligible authors: Corresponding authors who are teaching and research staff employed by or otherwise accredited to one of the participating institutions as well as students enrolled or accredited to one of the institutions and who want to publish open access articles.

Compliance with National Institutes of Health Accessibility Requirements
The National Institutes of Health (NIH) requires authors to submit the “post-print” (the final manuscript, in Word format, after peer-review and acceptance for publication but prior to the publisher’s copyediting, design, formatting, and other services) of research the NIH funds to a repository that is accessible online by all without charge. As a service to our authors, LWW will identify to the National Library of Medicine (NLM) articles that require deposit and will transmit the post-print of an article based on research funded in whole or in part by the NIH to PubMed Central.

FAQ for open access
https://www.wolterskluwer.com/en/solutions/lippincott-journals/lippincott-open-access/faq

Permissions: Authors must submit written permission from the copyright owner (usually the publisher) to use direct quotations, tables, or illustrations that have appeared in copyrighted form elsewhere, along with complete details about the source. Any permissions fees that might be required by the copyright owner are the responsibility of the authors requesting use of the borrowed material, not the responsibility of Lippincott Williams & Wilkins.

Manuscript Submission

Article Types:
Manuscripts under the following categories are invited or selected by the Editor or Section Editors:
1. Contact Allergen of the Year
2. Contact Allergen Alternatives
3. Editorials

Manuscripts under the following categories may be submitted independently. Please note requirements specific to each manuscript type.

1. Reviews

Requires unstructured abstract of 150 words or less.
Also required, a capsule summary of 2 or 3 bullet points which summarize the majors points of the article

2. Studies

Requires structured abstract of 200 words or less:
Background – Describe the primary concern or question that prompted the study.
Objective – State the purpose of the study.
Methods – Summarize the methods.
Results – Summarize the results.
Conclusions – Briefly state the most important conclusion.
Also required, a capsule summary of 2 or 3 bullet points which summarize the majors points of the article

3. Case Reports

Requires unstructured abstract of 150 words or less.
Note – At editor’s discretion, may be published online
only.

4. Pearls & Zebra

No abstract
5 references or less.
Submissions should strictly follow the following format:
Precis - Initial sentence of 25 words or less stating why the paper needs be published
Discussion – Description and discussion of the case in 500 words or less.
Pearl or Zebra - Concluding sentence of 25 words or less stating why the case is a is a Pearl (provide insight into understanding disease pathogenesis or improving treatment) or a Zebra (cases that inform about previously unrecognized conditions or atypical variants of known conditions).

5. Images in Dermatitis

This feature is intended to provide a high-quality visual image of an interesting and unique dermatological observation related to Contact, Occupational, Atopic and Drug-induced dermatitis. These include clinical images of skin diseases (ie, photographs, photomicrographs, and other images) that enhance the understanding of cutaneous pathophysiology and improve clinicians' ability to diagnose and treat skin disorders.
Up to a 500-word description of the clinical issue, the patient's presentation and findings, and the images should be included. There should be no more than 2 images (figures), 5 references, and no more than 3 authors. Online supplementary material is not allowed.
For DERMATITIS, the images should address one or more of the four major areas of focus of our journal (Contact, Occupational, Atopic and Drug).  The Images will be published in the print version of DERMATITIS and will be posted at the journal website to develop an image gallery.
If the patient(s) described in these manuscripts is identifiable, a Patient Permission form must be completed and signed by the patient(s) and submitted with the manuscript. Omitting data or making data less specific to de-identify patients is acceptable but changing any such data is not acceptable.

6. Letters

No abstract
Maximum Word count - 500 words
5 references or less.
Only one figure and/or table allowed

On-line manuscript submission:
All manuscripts must be submitted on-line through the new web site at https://der.edmgr.com/.

First-time users: Please click the Register button from the menu above and enter the requested information. On successful registration, you will be sent an e-mail indicating your user name and password. Note: If you have received an e-mail from us with an assigned user ID and password, or if you are a repeat user, do not register again. Just log in. Once you have an assigned ID and password, you do not have to re-register, even if your status changes (that is, author, reviewer, or editor).

Authors: Please click the log-in button from the menu at the top of the page and log in to the system as an Author. Submit your manuscript according to the author instructions. You will be able to track the progress of your manuscript through the system. If you experience any problems, please contact Jo Urquhart: [email protected], phone: 214-643-1858, fax: 214-648-5556.

Preparation of Manuscript
Title page: Include on a title page separate from your manuscript (a) the complete manuscript title; (b) authors' full names, highest academic degrees, and name of the institution in which work was done; (c) name and address for correspondence, including fax number, telephone number, and e-mail address; (d) address for reprints if different from that of corresponding author; and (e) all sources of support, including pharmaceutical and industry support, that require acknowledgment.

The title page must also include disclosure of all funding and/or conflicts of interest directly related to the work being submitted. This includes but is not limited to funding from any of the following organizations: National Institutes of Health (NIH); Wellcome Trust; Howard Hughes Medical Institute (HHMI); and other(s).

Abstract and key words: Limit the abstract to 200 words. Structured abstracts must be submitted for Studies as noted above. Do not cite references in the abstract. Limit the use of abbreviations and acronyms.

Figures:
A) Creating Digital Artwork

  1. Learn about the publication requirements for Digital Artwork: http://links.lww.com/ES/A42
  2. Create, Scan and Save your artwork and compare your final figure to the Digital Artwork Guideline Checklist (below).
  3. Upload each figure to Editorial Manager in conjunction with your manuscript text and tables.

B) Digital Artwork Guideline Checklist
Here are the basics to have in place before submitting your digital artwork:

Remember:

Figure legends: Include legends for all figures. They should be brief and specific, and they should appear on a separate manuscript page after the references.

Tables:
Create tables using the table creating and editing feature of your word processing software (eg, Word, WordPerfect). Do not use Excel or comparable spreadsheet programs. Group all tables in a separate file. Cite tables consecutively in the text, and number them in that order. Each table should appear on a separate sheet and should include the table title, appropriate column heads, and explanatory legends (including definitions of any abbreviations used). Do not embed tables within the body of the manuscript. They should be self-explanatory and should supplement, rather than duplicate, the material in the text.

References:
In the text, references should be numbered consecutively with superscript arabic numbers. A list of references should be compiled at the end of the article according to the order of citation in the text. It is preferred that references not be prepared with an electronic reference program. However, if one is used, the references must not be prepared as footnotes, or they cannot be accepted. The reference list should be typewritten, double-spaced, under the heading ‘‘References.’’

Journal
1. Davis JT, Allen HD, Powers JD, et al. Population requirements for capitation planning in cardiac surgery. Arch Pediatr Adolesc Med. 1996;150:257–259.

Chapter in a book
2. Nahas GG, Goldfrank LR. Marijuana. In: Goldfrank LR, Flomenbaum NE, Lewin NA, et al, eds. Goldfrank’s Toxicologic Emergencies. 5th ed. Norwalk, CT: Appleton & Lange; 1994:889–898.

Book
3. Sherlock S, Dooley J. Diseases of the Liver and Biliary System. 9th ed. Oxford, England: Blackwell Scientific Publications; 1993.

Software
4. Epi Info [computer program]. Version 6. Atlanta, GA: Centers for Disease Control and Prevention; 1994.

Online journals
5. Friedman SA. Preeclampsia: a review of the role of prostaglandins. Obstet Gynecol [serial online]. January 1988;71:22-37. Available from: BRS Information Technologies, McLean, VA. Accessed December 15, 1990.

Database
6. CANCERNET-PDQ [database online]. Bethesda, MD: National Cancer Institute; 1996. Updated March 29, 1996.

World Wide Web
7. Gostin LO. Drug use and HIV/AIDS [JAMA HIV/AIDS Web site]. June 1, 1996. Available at: http://www.ama-assn.org/special/hiv/ethics. Accessed June 26, 1997.

URL (uniform resource locator)
8. (J. M. Kramer, K. Kramer [[email protected]], e-mail, March 6, 1996).

Style:
In general, style should be patterned after the American Medical Association Manual of Style (9th edition). Please see the LWW Style Guide for further information.

Drugs and therapeutic agents should be referred to by their accepted generic or chemical names. The name should not be abbreviated. Code numbers should be used only when a generic name is not yet available. In that case, the chemical name and a figure giving the chemical structure of the drug is required. Copyright or trade names of drugs should be capitalized and placed in parentheses after the name of the drug. Names and locations (city and state in USA; city and country outside USA) of manufacturers of drugs, supplies, or equipment cited in a manuscript are required to comply with trademark law and should be provided in parentheses. Units of measure should be expressed in the metric system, and temperatures should be expressed in degrees Celsius. Conventional units should be written as SI units as appropriate.

After Acceptance:

Page proofs and corrections: Corresponding authors will receive electronic page proofs to check the copyedited and typeset article before publication. Portable document format (PDF) files of the typeset pages and support documents (e.g., reprint order form) will be sent to the corresponding author via e-mail. Complete instructions will be provided with the e-mail for downloading and marking the electronic page proofs. Corresponding author must provide an email address. The proof/correction process is done electronically.

It is the author's responsibility to ensure that there are no errors in the proofs. Authors who are not native English speakers are strongly encouraged to have their manuscript carefully edited by a native English-speaking colleague. Changes that have been made to conform to journal style will stand if they do not alter the authors' meaning. Only the most critical changes to the accuracy of the content will be made. Changes that are stylistic or are a reworking of previously accepted material will be disallowed. The publisher reserves the right to deny any changes that do not affect the accuracy of the content. Authors may be charged for alterations to the proofs beyond those required to correct errors or to answer queries. Electronic proofs must be checked carefully and corrections returned within 24 to 48 hours of receipt, as requested in the cover letter accompanying the page proofs.

Publisher's contact: Return corrected page proofs, color proofs, reprint order forms, and any other related materials to:

Brittney Patrick
Journal Production Editor
Wolters Kluwer Health Medical Research
Two Commerce Square
2001 Market Street
Philadelphia, PA 19103
Email: [email protected].

Reprints: Authors will receive an email notification with a link to the order form soon after their article publishes in the journal (https://shop.lww.com/author-reprint). Reprints are normally shipped 6 to 8 weeks after publication of the issue in which the item appears. Contact the Reprint Department, Lippincott Williams & Wilkins, 351 W. Camden Street, Baltimore, MD 21201; Fax: 410.558.6234; E-mail: [email protected] with any questions.